Notícias e Atividades da Cyclerion Therapeutics

Cyclerion Therapeutics é uma empresa listada sob o símbolo CYCN (US).

Fusão, aquisição e financiamento envolvendo Cyclerion Therapeutics.

• Korsana Biosciences and Cyclerion Therapeutics have merged  (publicado em 2 de abril de 2026)..

Veja o organograma con seus 7 executivos principais

Biografias mais buscadas da Cyclerion Therapeutics

• Regina Graul, President and Chief Executive Officer and Director
• Peter Hecht, Director
• Dina Katabi, Director

Criar um alerta
para seguir os movimentos de executivos da Cyclerion Therapeutics.

Cyclerion Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Cyclerion Therapeutics

• Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects | Cyclerion Therapeutics, Inc.
• Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease | Cyclerion Therapeutics, Inc.
• Cyclerion to Participate at Upcoming September 2020 Investor Conferences | Cyclerion Therapeutics, Inc.
• Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program | Cyclerion Therapeutics, Inc.
• Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights | Cyclerion Therapeutics, Inc.
• Cyclerion Therapeutics Completes $24 Million Private Placement | Cyclerion Therapeutics, Inc.
• Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer’s Disease Summit | Cyclerion Therapeutics, Inc.
• Cyclerion to Host Webcast Investor Event on July 9, 2020 | Cyclerion Therapeutics, Inc.
• Cyclerion Updates Corporate Progress | Cyclerion Therapeutics, Inc.
• Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases | Cyclerion Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Cyclerion Therapeutics

• Cyclerion Therapeutics na Wikipedia, Google News e Yahoo Finance
• Cyclerion Therapeutics na LinkedIn, X (Twitter) e YouTube